SurModics Stock News

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Surmodics, Inc. (SRDX Quick QuoteSRDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimi

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima

SurModics (SRDX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to loss of $0.40 per share a year ago.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today report

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announ

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that managem

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est

SurModics (SRDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.50 per share a year ago.